文献速递腹部技术与安全PETCT

氟18标记氟代脱氧葡萄糖、碳11标记乙酸盐与镓68标记成纤维细胞激活蛋白抑制剂-04 PET/CT对肝细胞癌的预后与诊断价值

Prognostic and diagnostic value of [18F]FDG, 11C-acetate, and [68Ga]Ga-FAPI-04 PET/CT for hepatocellular carcinoma.
PubMed 文献 · Eur Radiol · 2025-01-21

前瞻性纳入2021年5月至2022年9月间36例疑似肝脏肿块患者,术前均行三种示踪剂PET/CT。29例确诊肝细胞癌,碳11标记乙酸盐或镓68标记成纤维细胞激活蛋白抑制剂-04阴性者总生存更差;双示踪剂镓68标记成纤维细胞激活蛋白抑制剂-04联合碳11标记乙酸盐敏感度最高,44个病灶中检出39个(88.6%)。

要点

  • 肝细胞癌病灶碳11标记乙酸盐或镓68标记成纤维细胞激活蛋白抑制剂-04阴性提示总生存更差。
  • 双示踪剂镓68标记成纤维细胞激活蛋白抑制剂-04联合碳11标记乙酸盐方案敏感度最高,44个病灶中检出39个(88.6%)。
  • 组织学分级更高和伴微血管侵犯的肝细胞癌病灶氟18标记氟代脱氧葡萄糖的SUVmax与肿瘤/本底比值更高。

核心结论

  • 镓68标记成纤维细胞激活蛋白抑制剂-04与碳11标记乙酸盐PET/CT对肝细胞癌患者有良好预测价值,两者联合对肝细胞癌检出敏感度最高,提示可能改进诊断方案。

研究设计与样本

  • 前瞻性研究,2021年5月至2022年9月纳入36例疑似肝脏肿块患者,术前均行氟18标记氟代脱氧葡萄糖、镓68标记成纤维细胞激活蛋白抑制剂-04与碳11标记乙酸盐PET/CT,PET/CT结果与组织病理分别由两名放射科医师与病理科医师独立判读。

关键影像表现/征象

  • 组织学分级更高的肝细胞癌病灶氟18标记氟代脱氧葡萄糖的SUVmax与肿瘤/本底比值更高。
  • 伴微血管侵犯的肝细胞癌病灶氟18标记氟代脱氧葡萄糖的SUVmax与肿瘤/本底比值更高。
  • 镓68标记成纤维细胞激活蛋白抑制剂-04与碳11标记乙酸盐PET/CT在组织学分级更高和伴微血管侵犯的病灶中未见显著差异的证据。
  • 成纤维细胞激活蛋白表达更高者镓68标记成纤维细胞激活蛋白抑制剂-04与氟18标记氟代脱氧葡萄糖摄取更高。

诊断标准与关键数值

  • 双示踪剂镓68标记成纤维细胞激活蛋白抑制剂-04联合碳11标记乙酸盐方案敏感度最高,44个肝细胞癌病灶中检出39个(88.6%)。
  • 36例患者中29例诊断为肝细胞癌,4例为非肝细胞癌恶性肿瘤,3例为良性肿瘤。

临床应用与阅片要点

  • 作者认为镓68标记成纤维细胞激活蛋白抑制剂-04与碳11标记乙酸盐联合对肝细胞癌检出敏感度最高,提示可能改进诊断方案。
  • 碳11标记乙酸盐或镓68标记成纤维细胞激活蛋白抑制剂-04阴性可能与肝细胞癌患者总生存更差相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the prognostic value of Fluorine 18-labeled fluorodeoxyglucose [18F]FDG, gallium 68-labeled fibroblast-activation protein inhibitor-04 [68Ga]Ga-FAPI-04, 11C-acetate in hepatocellular carcinoma (HCC) and evaluate the potential usefulness and advantages of different combinations for accurate diagnosis.

MATERIALS AND METHODS: Thirty-six patients with suspected hepatic masses were prospectively enrolled from May 2021 to September 2022 and underwent [18F]FDG, [68Ga]Ga-FAPI-04, and 11C-acetate PET/CT scans before surgery. PET/CT results and histopathologic examinations were independently interpreted by two radiologists and pathologists, respectively. Kaplan-Meier overall survival curves were calculated and the sensitivity among [18F]FDG, 11C-acetate, [68Ga]Ga-FAPI-04, and different combinations were compared.

RESULTS: Of the 36 included patients (mean age, 59 years ± 10 (standard deviation)), 29 were diagnosed with HCC, four with non-HCC malignant tumors, and three with benign tumors. Patients with HCC lesions negative for 11C-acetate or [68Ga]Ga-FAPI-04 exhibited poorer overall survival. Out of 36 patients, 44 HCC lesions were detected. The dual-tracer [68Ga]Ga-FAPI-04/11C-acetate exhibited the highest sensitivity (39 of 44 lesions (88.6%)) among all schemes. HCC lesions with higher histological grade and microvascular invasion (MVI) showed higher maximum standardized uptake value (SUVmax) and tumor-to-background ratio (TBR) of [18F]FDG, but no evidence of significant differences was found in [68Ga]Ga-FAPI-04 and 11C-acetate PET/CT. Higher expression of fibroblast activation protein (FAP) showed higher uptake of [68Ga]Ga-FAPI-04 and [18F]FDG.

CONCLUSION: [68Ga]Ga-FAPI-04 and 11C-acetate PET/CT exhibited good predictive value for HCC patients, with their combination showing the highest sensitivity for HCC detection, suggesting potential for improved diagnostic protocols.

KEY POINTS: Question What are the prognostic and diagnostic values of PET/CT tracers, including [18F]FDG, [68Ga]FAPI-04, and 11C-acetate? Findings Hepatocellular carcinoma, with differing findings across [18F]FDG, [68Ga]GaFAPI-04, and 11C-acetate PET/CT, showed varied prognoses; [68Ga]GaFAPI-04 and 11C-acetate combined offered the highest detection sensitivity. Clinical relevance Evaluating the prognostic value and diagnostic efficacy of different tracer combinations in patients with hepatocellular carcinoma helps to guide the optimal selection of tracers in clinical practice.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Xu H, Wang H, Yu SZ, et al. Prognostic and diagnostic value of [18F]FDG, 11C-acetate, and [68Ga]Ga-FAPI-04 PET/CT for hepatocellular carcinoma. Eur Radiol. 2025. PMID: 39838091. doi:10.1007/s00330-025-11352-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。